On December 5th, at the invitation of Dr. Benjamin Hua, President of DALTONbio and Chairman of the Biopharmaceutical Innovation Association (BIA), a delegation of international gynecology and oncology experts visited DALTONbio. The delegation included Professor Agnaldo Lopes da Silva Filho, former President and current Scientific Director of the Brazilian Federation of Gynecology and Obstetrics (FEBRASGO); Professor Omar A. Zayas Villanueva from the Department of Obstetrics and Gynecology at UANL University Hospital in Mexico; as well as Dr. Sunnorin Kang and Dr. Sokban Chek from the Cancer Center at the Queen Mother Hospital in Cambodia. Leaders and senior executives from in vitro diagnostics (IVD) and medical device companies, including Shengyu Medical, JoinStar, Zheda Dixun Biological Gene Engineering, and Expeclin, warmly welcomed the visiting experts.

At the opening of the symposium, Dr. Hua introduced Hangzhou as one of China’s leading cities in cutting-edge technology and manufacturing, with significant advantages in talent, policies, and industrial support. He emphasized that the biopharmaceutical industry is a key focus for the future development of Hangzhou and Zhejiang Province. After years of technological advancement, “Made in China” has achieved world-class standards in certain IVD fields, such as cervical cancer screening technology, mass spectrometry, point-of-care testing (POCT), and allergen detection. Hangzhou’s IVD professionals demonstrate forward-thinking technical concepts, a customer-oriented service mindset, and efficient execution capabilities. Dr. Hua expressed hope that the visiting experts could share insights into global clinical and technological trends while gaining a deeper understanding of the Hangzhou IVD industry’s development, paving the way for international collaborations.

The four international experts provided an overview of the current state of their respective academic fields in their home countries. The primary goal of their visit was to gain an in-depth and objective understanding of “Made in China” innovations, particularly Hangzhou’s advanced IVD technologies, through an immersive experience. Their visit aimed to foster multi-dimensional cooperation between Chinese enterprises and global healthcare needs.

Following the symposium, the visiting experts engaged in enthusiastic discussions with corporate representatives, actively exploring opportunities for future academic collaboration. Events like this will continue to serve as a bridge for DALTONbio and BIA member companies to form synergies, fostering deeper cooperation with international partners. Moving beyond simple market expansion, this collaboration marks a step toward a more profound level of globalization, writing a new chapter in global development.